Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Zaleplon chemical structure
| N-(3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl)phenyl)-N- ethylacetamide|
| CAS number |
| ATC code |
| PubChem |
| DrugBank |
|Elimination half-life||1 hour|
|Routes of administration||Oral|
Zaleplon (marketed under the brand names Sonata and Starnoc) is a sedative/hypnotic, mainly used for insomnia. It is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class. Zaleplon is one of few sleep medications which have been found to not cause an increase in road traffic accidents, thus demonstrating a much higher safety profile than many other hypnotics currently on the market.
Sonata (US) is manufactured by King Pharm. of Bristol, TN; Starnoc has been discontinued in Canada.
Pure zaleplon in its solid state is a white to off-white powder that has very low solubility in water as well as low solubility in alcohol and propylene glycol. It has a partition coefficient in octanol/water that is constant (log PC = 1.23) when the pH range is between 1 and 7.
Zaleplon is efficacious in the treatment of insomnia where difficulty in falling asleep is the primary complaint. Zaleplon, unlike many other hypnotic drugs, does not interfere with sleep architecture and can be administered for up to 5 weeks without the risk of dependence or rebound insomnia upon discontinuation.
Zaleplon selectively binds with high efficacy to the benzodiazepine site (ω1) on the α1 containing GABAA receptors which produces its therapeutic hypnotic properties. The ultra short half life gives zaleplon a unique advantage over other hypnotics because of its lack of next day residual effects on driving and other performance related skills. Unlike non-selective benzodiazepine drugs and zopiclone which distort the sleep pattern zaleplon appears to induce sleep without disrupting the natural sleep architecture.
A meta-analysis of randomised controlled clinical trials which compared benzodiazepines against Zaleplon or other Z Drugs such as zolpidem and zopiclone, has found that there are few clear and consistent differences between Zaleplon and the benzodiazepines in terms of sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse events, tolerance, rebound insomnia and daytime alertness.
Zaleplon has a pharmacological profile similar to benzodiazepines, that is characterized by an increase in SWDS with rapid onset of hypnotic action. Zaleplon is a full agonist for the benzodiazepine α1 receptor located on the GABAA receptor ionophore complex in the brain, with lower affinity for the α2 and α3 subtypes. It selectively enhances the action of GABA similar to but more selectively than benzodiazepines. Zaleplon, although not benzodiazepine-like in chemical structure induces sedative-hypnotic, anticonvulsant and anticonflict effects via its binding to the central nervous system (CNS) type benzodiazepine receptors. The elimination half life of zaleplon is 1 hour. Absorption is rapid. Zaleplon can be classed as an ultra short acting sedative hypnotic drug for the treatment of insomnia characterised by difficulty in falling asleep. Zaleplon increases EEG power density in the delta frequency band and a decrease in the energy of the theta frequency band. In tests on rabbits zaleplon shows drowsy pattern of spontaneous EEG characterized by high-voltage slow waves and desynchronization of hippocampal theta waves and an increase in the energy of the delta frequency band on the spectral analysis of the electroencephalogram.
Zaleplon is primarily metabolised by aldehyde oxidase, and its half-life can be affected by substances which inhibit or induce aldehyde oxidase. Taken orally, zaleplon reaches full concentration in approximately one hour. It is extensively metabolised, into 5-oxo-zaleplon and 5-oxo-desethylzaleplon (the latter via desethylzaleplon), with less than 1% of it excreted intact in urine.
An extensive review of the medical literature regarding the management of insomnia and the elderly found that there is considerable evidence of the effectiveness and durability of non-drug treatments for insomnia in adults of all ages and that these interventions are underutilized. Compared with the benzodiazepines, the nonbenzodiazepine (including zaleplon) sedative-hypnotics appeared to offer few, if any, significant clinical advantages in efficacy or tolerability in elderly persons. It was found that newer agents with novel mechanisms of action and improved safety profiles, such as the melatonin agonists, hold promise for the management of chronic insomnia in elderly people. Long-term use of sedative-hypnotics for insomnia lacks an evidence base and has traditionally been discouraged for reasons that include concerns about such potential adverse drug effects as cognitive impairment (anterograde amnesia), daytime sedation, motor incoordination, and increased risk of motor vehicle accidents and falls. In addition, the effectiveness and safety of long-term use of these agents remain to be determined. It was concluded that more research is needed to evaluate the long-term effects of treatment and the most appropriate management strategy for elderly persons with chronic insomnia.
The side effects of zaleplon are similar to the side effects of benzodiazepines.
Zaleplon may cause hallucinations, abnormal behavior, severe confusion, day-time drowsiness, dizziness or lightheadedness, unsteadiness and/or falls, double vision or other vision problems, agitation, headache, nausea, vomiting, diarrhea or abdominal pain, depression, muscle weakness, tremor, vivid or abnormal dreams and memory difficulties or amnesia.
Zaleplon is habit-forming, meaning addiction or drug dependence may occur. Stopping this medication suddenly after prolonged or frequent use may cause withdrawal effects such as mood changes, anxiety, restlessness or rebound insomnia.
The elderly are more sensitive to the adverse effects of zaleplon such as cognitive side effects. Zaleplon may increase the risk of falls in the elderly.
Recreational useEditZaleplon (Sonata) has a relatively high potential to be abused. Often this use involves a different delivery method (insufflating) to induce effects faster.
The effects of Zaleplon are simliar to those of many other benzopdiazepines but the fast-acting nature and short half-life of the chemical mean that high dosages set on much more quickly and last for short periods of time (usually from 45 to 60 minutes). Insufflating the drug causes effects to happen even more quickly, and last for even shorter periods of time, with some loss of yield as Zaleplon is not entirely water soluable. Anterograde amnesia is very common, and can cause one to lose track of the amount of Zaleplon already ingested, causing them to ingest more than originally planned.
- ↑ Elie R, Rüther E, Farr I, Emilien G, Salinas E (Aug 1999). Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry: 536–44.
- ↑ Menzin J, Lang KM, Levy P, Levy E (January 2001). A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France. Pharmacoeconomics 19 (1): 69–78.
- ↑ Vermeeren A, Riedel WJ, van Boxtel MP, Darwish M, Paty I, Patat A (March 2002). Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 25 (2): 224–31.
- ↑ Walsh JK, Vogel GW, Scharf M, Erman M, William Erwin C , Schweitzer PK, Mangano RM, Roth T (February 2000). A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 1: 41–49.
- ↑ Walsh JK, Pollak CP, Scharf MB, Schweitzer PK, Vogel GW (Jan-Feb 2000). Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 23: 17–21.
- ↑ Verster JC, Veldhuijzen DS, Volkerts ER (August 2004). Residual effects of sleep medication on driving ability. Sleep Med Rev 8 (4): 309–25.
- ↑ Barbera J, Shapiro C (2005). Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf 28 (4): 301–18.
- ↑ Patat A, Paty I, Hindmarch I (July 2001). Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent. Hum Psychopharmacol 16 (5): 369–392.
- ↑ Rowlett JK, Spealman RD, Lelas S, Cook JM, Yin W (January 2003). Discriminative stimulus effects of zolpidem in squirrel monkeys: role of GABA(A)/alpha1 receptors. Psychopharmacology (Berl.) 165 (3): 209–15.
- ↑ Noguchi H, Kitazumi K, Mori M, Shiba T (January 2002). Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic. Eur. J. Pharmacol. 434 (1-2): 21–8.
- ↑ Dündar, Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T. (July 2004). Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 19 (5): 305–22.
- ↑ Noguchi H, Kitazumi K, Mori M, Shiba T. (March 2004). Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats. J Pharmacol Sci. 94 (3): 246–51.
- ↑ Petroski RE, Pomeroy JE, Das R, et al (April 2006). Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors. J. Pharmacol. Exp. Ther. 317 (1): 369–77.
- ↑ Bain KT (June 2006). Management of chronic insomnia in elderly persons. Am J Geriatr Pharmacother 4 (2): 168–92.
- ↑ Wagner J, Wagner ML, Hening WA (June 1998). Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother: 680–91.
- ↑ Kirkwood CK (Sep-Oct 1999). Management of insomnia. J Am Pharm Assoc (Wash): 688–96.
- ↑ Antai-Otong D (August 2006). The art of prescribing. Risks and benefits of non-benzodiazepine receptor agonists in the treatment of acute primary insomnia in older adults. Perspect Psychiatr Care 42 (3): 196–200.
- ↑ Wang JS, DeVane CL (2003). Pharmacokinetics and drug interactions of the sedative hypnotics. Psychopharmacol Bull 37 (1): 10–29.
- ↑ Rush CR, Frey JM, Griffiths RR (Jul 1999). Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology (Berl) 145: 39–51.
- ↑ Ator NA (2000). Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons. Drug Alcohol Depend 61: 55–68.
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|